Indication intelligence, analysis and sector perception

UniQure’s (QURE) gene therapy boosts clotting in two Hemophiliacs

January 7, 2016 1:24pm

UP +$1.56 on +10.46% on large volume as traders are selling into strength - HOLD

QURE’s experimental treatment for hemophilia B increased blood clotting ability in … two (2) patients.

The therapy, known as AMT-060, was designed to fix a genetic flaw caused by missing or defective factor IX, a protein that clots blood.

The Bottom Line: The two adult patients received a low dose of the treatment. Factor IX rose to 5.5% and 4.5% of the normal level from less than 2% in the patients. Three other people who received a low dose of the therapy in the trial haven’t yet reached the full 12 weeks of follow-up.

Factor IX levels of more than 5% are considered a mild form of the disease, which results in bleeding happening only rarely, QURE plans to start enrolling patients who will receive a higher dose of the therapy in the trial this quarter.

QURE is trading +$1.56 to $16.47 on HUGE volume <1.781 M share volume (3 month average = 353.5 K shares) having risen as high as $18.10 in pre-market trading, up from its Wednesday closing price of $14.91. The current trading range is $15.88 to $17.77 as many have been selling into strength.

Gene therapies have shown mixed results today and in recent months ... AGTC is DOWN -$1.60, ONCE is DOWN -$4.17 and BLUE is DOWN -$4.19.

HOLD on to your seat at this table!

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.